ALK B ALK-ABELLO A/S

ALK – Financial calendar for the 2026 financial year

ALK – Financial calendar for the 2026 financial year

2026 financial calendar for ALK (ALKB:DC / OMX: ALK B):

  • 23 January 2026:                      Silent period                       
  • 20 February 2026:                    Annual report 2025             
  • 16 March 2026 at 4.00 p.m.:     Annual General Meeting



Written requests to have specific business

transacted at the AGM will be included in the

agenda if received by the company on

30 January 2026 at the latest

(may be emailed to )



  • 7 April 2026:                             Silent period                       
  • 5 May 2026:                             Three-month interim report (Q1) 2026             
  • 23 July 2026:                            Silent period                       
  • 20 August 2026:                       Six-month interim report (Q2) 2026                 
  • 21 October 2026:                      Silent period                       
  • 18 November 2026:                  Nine-month interim report (Q3) 2026              

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
22/12/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK – Finanskalender for regnskabsåret 2026

ALK – Finanskalender for regnskabsåret 2026 Finanskalender 2026 for ALK (ALKB:DC / OMX: ALK B): 23. januar 2026:                Stilleperiode20. februar 2026:               Offentliggørelse af årsrapport 202516. marts 2026 kl. 16.00:   Ordinær generalforsamling Indkomne forslag til dagsordenen for den ordinære generalforsamling, der er modtagetaf selskabet senest den 30. januar 2026, vil blive optaget på dagsordenen(kan fremsættes på )  7. april 2026:                     Stilleperiode5. maj 2026:                      Delårsrapport 1. kvartal (Q1) 202623. juli 2026:                   ...

December 22, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK – Financial calendar for the 2026 financial year

ALK – Financial calendar for the 2026 financial year 2026 financial calendar for ALK (ALKB:DC / OMX: ALK B): 23 January 2026:                      Silent period                       20 February 2026:                    Annual report 2025             16 March 2026 at 4.00 p.m.:     Annual General Meeting Written requests to have specific business transacted at the AGM will be included in theagenda if received by the company on30 January 2026 at the latest(may be emailed to ) 7 April 2026:                             Silent period                       5 May 2026:                        ...

December 22, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Storaktionærmeddelelse

Storaktionærmeddelelse I henhold til § 30 i Lov om kapitalmarkeder skal ALK (ALKB:DC / OMX: ALK B) hermed oplyse, at Arbejdsmarkedets Tillægspension (“ATP”) har meddelt, at ATP har reduceret sin ejerandel i ALK til under 5% af aktiekapitalen (tidligere 5,0%). Meddelelsen fra ATP er vedhæftet denne selskabsmeddelelse. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fokus på allergi og allergisk astma. Virks...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension (“ATP”) (The Danish Supplementary Labour Market Pension) has informed ALK that ATP has reduced its ownership in ALK to below 5% of the share capital (previously 5.0%). The notification (in Danish) from ATP is attached to this company release. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty ...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK udnævner Edward Jordan til ny direktør for de kommercielle aktivit...

ALK udnævner Edward Jordan til ny direktør for de kommercielle aktiviteter i Nordamerika ALK (ALKB:DC / OMX: ALK B) har i dag annonceret udnævnelsen af Edward Jordan til ny Executive Vice President (EVP) og direktør for de kommercielle aktiviteter i Nordamerika med virkning fra 5. januar 2026. Edward Jordan afløser Søren Niegel, som midlertidigt har varetaget rollen i forlængelse af beslutningen, gældende fra 1. oktober 2025, om at inkludere ALK's to centrale kommercielle regioner, Europa og Nordamerika, i selskabets topledelse (Executive Leadership Team, ELT) for yderligere at styrke eksek...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch